Upconverting Phosphor Labels for Bioanalytical Assays

2013 ◽  
pp. 155-204 ◽  
Author(s):  
Terhi Riuttamäki ◽  
Tero Soukka
Keyword(s):  
INDIAN DRUGS ◽  
2019 ◽  
Vol 56 (07) ◽  
pp. 80-83
Author(s):  
W. A Zaghary ◽  
S. Mowaka ◽  
M. S. Hendy ◽  

Sodium glucose co-transporter-2 (SGLT-2) inhibitors are relatively new developed effective oral anti-diabetic agents used in treatment of type 2 Diabetes Mellitus. They present either alone or in combination with other ant diabetic agents such as linagliptin, Saxagliptin and metformin. Therefore, the necessity to explore and compare the existing analytical and bioanalytical assays used for determination of such drugs either single or in combination is crucial. Many methods were reported in the literature for the bio-analysis and analysis of three novel gliflozins with applying the method on different dosage forms and different chemical and biological samples. Furthermore, this review offered an overview of different methods used for determination of every drug alone in a tabulated comparative way. Moreover, the present review emphasized the most common stability indicating assays to be of interest to the analysts in the area of drug control.


Bioanalysis ◽  
2014 ◽  
Vol 6 (7) ◽  
pp. 993-1010 ◽  
Author(s):  
JJMA Hendrikx ◽  
H Rosing ◽  
AH Schinkel ◽  
JHM Schellens ◽  
JH Beijnen

Langmuir ◽  
2005 ◽  
Vol 21 (10) ◽  
pp. 4277-4280 ◽  
Author(s):  
Liane M. Rossi ◽  
Lifang Shi ◽  
Frank H. Quina ◽  
Zeev Rosenzweig

Lab on a Chip ◽  
2014 ◽  
Vol 14 (19) ◽  
pp. 3750 ◽  
Author(s):  
Matthias Geissler ◽  
Kebin Li ◽  
Xuefeng Zhang ◽  
Liviu Clime ◽  
Gregg P. Robideau ◽  
...  

Author(s):  
Heinz Jürgen Skrzipczyk ◽  
Patrick Verdier
Keyword(s):  

2020 ◽  
Vol 12 (1) ◽  
pp. e2020016
Author(s):  
Hui Liu ◽  
Lorraine Gemmell ◽  
Rui Lin ◽  
Fengrong Zuo ◽  
Henry H. Balfour ◽  
...  

No licensed vaccine is available for prevention of EBV-associated diseases, and robust, sensitive, and high-throughput bioanalytical assays are needed to evaluate immunogenicity of gp350 subunit-based candidate EBV vaccines. Here we have developed and improved analytical tools for such a vaccine’s pre-clinical and clinical validation including a gp350-specific antibody detection assay and an EBV-GFP based neutralization assay for measuring EBV specific antibodies in human donors. The sensitivity of our previously published high-throughput EBV-GFP fluorescent focus (FFA)-based neutralization assay was further improved when guinea pig complement was supplemented using a panel of healthy human sera. Anti-gp350 antibody titers, which were evaluated using an anti-gp350 IgG ELISA assay optimized for capture and detection conditions, were moderately correlated to the FFA-based neutralization titers. Overall, these sensitive, and high-throughput bioanalytical assays are capable of characterizing the serologic response to natural EBV infection, with applications in evaluating EBV antibody status in epidemiologic studies and immunogenicity of candidate gp350-subunit EBV vaccines in clinical studies.


Sign in / Sign up

Export Citation Format

Share Document